Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 14 Nov 2013 |
| Genmab to Present at Jefferies 2013 Global Healthcare Conference in London | 13 Nov 2013 |
| Capital Increase in Genmab as a Result of Employee Warrant Exercise and Projection of Improved Cash Position at the End of 2013 | 13 Nov 2013 |
| Genmab to Present Product and Proprietary Technology data at American Society of Hematology Annual Meeting (ASH) | 7 Nov 2013 |
| Genmab Announces Financial Results for the First Nine Months of 2013 | 6 Nov 2013 |